The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

While many recognize Mia Hamm as a legendary soccer player and two-time Olympic gold medalist, she has also become a ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Skinny jab? Try skinny juice. For centuries, it’s been enjoyed by people in South America — and it’s long been linked to ...

An estimated 15 million Americans are currently taking semaglutide weight loss drugs, which are proven to impact alcohol ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Medical professionals point out that functional impairment in individuals with PAD is often overlooked in its early stages ...

A GLP-1 oral medication claims to cut the risk of cardiovascular complications, like heart attacks and strokes, by 14% for people with diabetes and heart or kidney disease, per CNBC.